Trial Profile
Phase I trial evaluating the pharmacokinetics and metabolic profile of laninamivir octanoate following an inhaled dose administered via TwinCaps.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors Aviragen Therapeutics
- 22 Feb 2013 New trial record
- 12 Feb 2013 Topline are expected to be available in mid-2013, according to a Biota Pharmaceuticals media release.